# A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.

> **NCT04179409** · PHASE2 · COMPLETED · sponsor: **Kevin Flanigan** · enrollment: 3 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** Amondys 45
- **DRUG:** Exondys 51
- **DRUG:** Vyondys 53

## Key facts

- **NCT ID:** NCT04179409
- **Lead sponsor:** Kevin Flanigan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-18
- **Primary completion:** 2021-09-01
- **Final completion:** 2023-09-01
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2023-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04179409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04179409, "A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04179409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*